Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition

Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Hua Cai, Rongrong Zheng, Ningxia Wu, Jiaman Hu, Ruixin Wang, Jianing Chi, Wei Zhang, Linping Zhao, Hong Cheng, Ali Chen, Shiying Li, Lin Xu
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Subjects:	anti-tumor hyperlipidemia tumor-targeted peptide nanomedicine Rapamycin proprotein convertase subtilisin/kexin type 9 (PCSK9)
Online Access:	https://www.mdpi.com/1999-4923/15/10/2377